ArticleThe American journal of gastroenterology2017
Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians.
Article in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- The incidence of chronic drug-induced liver injury: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Acute Liver Injury Following Outpatient Trimethoprim-Sulfamethoxazole Use for Small Intestinal Bacterial Overgrowth: A Case Report.Clinical case reports · 2026Article
- Aspartate aminotransferase and model for end-stage liver disease reliably predict mortality in drug-induced liver injury.Scientific reports · 2026Article
- Disparities and trends in drug-related adverse reaction mortality in the United States, 1999-2020.Therapeutic advances in drug safety · 2026Article
- Costs, Demographics, and Causative Agents in Patients Hospitalized for Drug Induced Liver Injury: Trends in a Large Academic Healthcare System.Clinical and experimental gastroenterology · 2026Article
- N-acetyltransferase (NAT) 1 and NAT2 enzyme activities drive interindividual variability in sulfamethoxazole N-acetylation.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Rapid-Onset Drug-Induced Liver Injury Following Amoxicillin-Clavulanate: A Case Report.Clinical case reports · 2025Article
- Prevalence of Polypharmacy Among Patients with Chronic Liver Disease-A Narrative Literature Review.Journal of clinical medicine · 2025Review
- Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury.iLIVER · 2024Article
- HLA-B*53:01 Is a Significant Risk Factor of Liver Injury due to Phenytoin and Other Antiepileptic Drugs in African Americans.The American journal of gastroenterology · 2024Article
- Turmeric-induced Liver Injury.Journal of community hospital internal medicine perspectives · 2024Article
- Preoperative risk evaluation and optimization for patients with liver disease.Gastroenterology report · 2024Review
- Systematic review and meta-analysis: Comparing hepatocellular and cholestatic patterns of drug-induced liver injury.iLIVER · 2023Article
- Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.Gastroenterology · 2023Article
- Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.Antimicrobial agents and chemotherapy · 2022Article
- Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.Antimicrobial agents and chemotherapy · 2022Article
- Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Secular Trends in Severe Idiosyncratic Drug-Induced Liver Injury in North America: An Update From the Acute Liver Failure Study Group Registry.The American journal of gastroenterology · 2022Article
- Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.Journal of hepatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
objectivesIdiosyncratic drug induced liver injury (DILI) is a rare but potentially serious liver disorder and a major cause of significant liver injury. Limited data exist on racial differences in DILI incidence, presentation, and course.
methodsWe compared the causative agents, clinical features, and outcomes of DILI among self-described African-Americans and non-Hispanic whites (Caucasians) enrolled in the DILIN Prospective Study. Individuals with definite, highly likely, or probable DILI enrolled between September 2004 and February 2016 were included in this analysis.
results144 African-Americans and 841 Caucasian patients met the eligibility criteria. Causal medications varied by race: trimethoprim/sulfamethoxazole being the most common cause among African-Americans (7.6 vs. 3.6%) followed by methyldopa (4 vs. <1%), phenytoin (5 vs. <1%), isoniazid (4 vs. 4%), and amoxicillin/clavulanate (4.1 vs. 13.4%). The severity of illness, however, tended to be greater in African-Americans than Caucasians as determined by peak mean bilirubin (14.3 vs. 12.8 mg/dl), INR (1.9 vs. 1.6), and DILIN severity score (3.0 vs. 2.6). The frequency of severe cutaneous reactions was significantly higher in African-Americans (2.1 vs. 0.36% in Caucasians, P=0.048). African-Americans also had higher rates of hospitalization (76.7 vs. 57.6%, P<0.001), liver transplantation or liver related death by 6 months (10.2 vs. 5.8%, P=0.02 after controlling for selected covariates), and chronic DILI (24 vs. 16%, P=0.06).
conclusionsThe most common DILI causative agents differ between African-Americans and Caucasians. African-Americans are more likely to have severe cutaneous reactions and more severe liver injury leading to worse outcomes, including death and liver transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.